Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (91-100 of 225) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2018
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell LymphomaMatthew S Davids, Gottfried von Keudell, Craig A Portell, et al.
Haematologica|October 15, 2020
A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockadePeter G Miller, Adam S Sperling, Christopher J Gibson, et al.
Blood Advances|April 19, 2024
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trialsMatthew S Davids, Jeff P Sharman, Paolo Ghia, et al.
Hemasphere|January 16, 2025
Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemiaChristine E Ryan, Yue Ren, Svitlana Tyekucheva, et al.
Ejhaem|July 18, 2022
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapySasanka Handunnetti, Mary Ann Anderson, Andrew W Roberts, et al.
British Journal of Haematology|November 28, 2018
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitorWilliam G Wierda, John C Byrd, Matthew S Davids, et al.
Blood Neoplasia|June 23, 2025
Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United StatesMatthew S Davids, Jacob Ambrose, Enrico de Nigris, et al.
Leukemia & Lymphoma|February 9, 2018
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect<sup>®</sup> CLL cohort studyChristopher R Flowers, Chadi Nabhan, Neil E Kay, et al.
Blood|August 3, 2016
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axisGabriela Pavlasova, Marek Borsky, Vaclav Seda, et al.
Genome Biology|April 16, 2026
Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemiaAnja C Rathgeber, Stacey M Fernandes, Adi Nagler, et al.
Pageof 23

Showing results (91-100 of 225) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2018
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell LymphomaMatthew S Davids, Gottfried von Keudell, Craig A Portell, et al.
Haematologica|October 15, 2020
A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockadePeter G Miller, Adam S Sperling, Christopher J Gibson, et al.
Blood Advances|April 19, 2024
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trialsMatthew S Davids, Jeff P Sharman, Paolo Ghia, et al.
Hemasphere|January 16, 2025
Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemiaChristine E Ryan, Yue Ren, Svitlana Tyekucheva, et al.
Ejhaem|July 18, 2022
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapySasanka Handunnetti, Mary Ann Anderson, Andrew W Roberts, et al.
British Journal of Haematology|November 28, 2018
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitorWilliam G Wierda, John C Byrd, Matthew S Davids, et al.
Blood Neoplasia|June 23, 2025
Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United StatesMatthew S Davids, Jacob Ambrose, Enrico de Nigris, et al.
Leukemia & Lymphoma|February 9, 2018
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect<sup>®</sup> CLL cohort studyChristopher R Flowers, Chadi Nabhan, Neil E Kay, et al.
Blood|August 3, 2016
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axisGabriela Pavlasova, Marek Borsky, Vaclav Seda, et al.
Genome Biology|April 16, 2026
Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemiaAnja C Rathgeber, Stacey M Fernandes, Adi Nagler, et al.
Pageof 23